Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARK7 | Q99497 | 1/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 6/20 | 0.49 |
| ▸ | AKR1A1 | P14550 | 5/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4164986 | 0.88 | PARK7 (0.64) | PARK7PTGDR2AKR1B1AKR1A1CNR1 | |
| SCHEMBL4174602 | 0.87 | ALDH1A1 (0.43) | PARK7PTGDR2AKR1B1AKR1A1ALDH1A1 | |
| SCHEMBL4255735 | 0.87 | TP53 (0.52) | PTGDR2AKR1B1AKR1A1CNR1ALDH1A1 | |
| SCHEMBL4169552 | 0.86 | AKR1B1 (0.45) | PARK7PTGDR2AKR1B1AKR1A1 | |
| SCHEMBL10955668 | 0.86 | AKR1B1 (0.47) | PARK7PTGDR2AKR1B1AKR1A1ALDH1A1 | |
| SCHEMBL4259885 | 0.86 | ADAMTS5 (0.52) | CNR1ALDH1A1 | |
| SCHEMBL11045654 | 0.86 | TP53 (0.54) | AKR1B1AKR1A1CNR1ALDH1A1ALPL | |
| SCHEMBL4255745 | 0.85 | AKR1B1 (0.47) | PARK7PTGDR2AKR1B1AKR1A1 | |
| SCHEMBL4259962 | 0.85 | AKR1A1 (0.50) | PTGDR2AKR1B1AKR1A1 | |
| SCHEMBL4254336 | 0.85 | ALDH1A1 (0.51) | CNR1ALDH1A1ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | claimed |
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | TRPV1, TRPV2, TRPV3 | PARK7 1812/4885PTGDR2 193/4885AKR1B1 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.